Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Fulfills at least 4 of the 11 American College of Rheumatology (ACR) criteria for systemic lupus erythematosus (SLE) including a positive antinuclear antibody (ANA) greater than or equal to 1:80 or elevated anti-double-stranded DNA or anti-Smith antibody at screening~* Pediatric or adult SLE with chronic disease activity for greater than or equal to 24 weeks~* Weight greater than or equal to 40 kg~* Currently receiving stable dose of oral prednisone (or equivalent) less than or equal to 40 mg/day and/or antimalarials/immunosuppressives~* Active moderate to severe SLE disease based on SLE disease activity score (SLEDAI) and British Isles Lupus Assessment Group Index (BILAG) and Physicians Global Assessment~* No evidence of cervical malignancy on Pap smear within 2 years of randomization~* Female participants must be willing to avoid pregnancy~* Negative tuberculosis (TB) test or newly positive TB test due to latent TB for which treatment must be initiated at or before randomization.~Exclusion Criteria:~* Active severe SLE-driven renal disease or unstable renal disease prior to screening~* Active severe or unstable neuropsychiatric SLE~* Clinically significant active infection including ongoing and chronic infections~* History of human immunodeficiency virus (HIV)~* Confirmed Positive tests for hepatitis B or positive test for hepatitis C~* History of severe herpes infection such as herpes encephalitis, ophthalmic herpes, disseminated herpes~* Live or attenuated vaccine within 4 weeks prior to screening~* Participants with significant hematologic abnormalities.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Anifrolumab (MEDI-546) 300 mg (Type: EXPERIMENTAL): Participants will receive 300 milligram (mg) anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
- Anifrolumab (MEDI-546) 1000 mg (Type: EXPERIMENTAL): Participants will receive 1000 mg anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
- Matching Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo matched to anifrolumab intravenous (IV) infusion every 4 weeks for 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).